Androgen and Reproductive Disorders Feature Archive
Although the use of fertility therapy has steadily increased in the past few decades, research findings pertaining to related long-term cardiovascular outcomes are scarce and conflicting.
Lifestyle modification and an individualized treatment approach are effective strategies for managing menopausal symptoms in breast cancer survivors who are largely advised to avoid hormone replacement therapy.
The relationship between hormones and migraine is most frequently pronounced during the female reproductive years.
A lack of data prevents endocrinologists from fully understanding the long-term risks of therapy in this patient population.
Sexual function and mood and depressive symptoms were improved in older men who received testosterone therapy.
An individualized approach based on patient preferences is important for treatment of menopause.
Selective estrogen receptor modulators may offer a viable treatment option for men with secondary hypogonadism.
Recent data suggest that older age at menopause as well as a longer reproductive period have a lower risk for depression later in life.
Preconception interventions designed to induce weight loss in women with PCOS improved metabolic parameters and ovulation rates.
American Association of Clinical Endocrinologists issues position statement on CV risks of testosterone therapy.
Women seeking relief from menopausal symptoms must be aware of the risks, benefits of different treatment options.
In older men, testosterone levels directly linked to sexual activity, desire.
Hypogonadism is disproportionately high in men with spinal cord injury, leading researchers to suggest a connection between the two conditions.
The use of non-FDA-approved, bioidentical hormone therapy is increasing dramatically among menopausal women.
Transgender persons are a unique patient population and require careful consideration when undergoing hormone therapy, such as estrogen and testosterone replacement.
The Menopause Map facilitates discussion between patients and providers on the "menopause journey."
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- New Romosozumab BLA Includes Data from Additional Osteoporosis Trials
- Impact of Maternal Diabetes on Outcomes in Very Preterm, Very Low-Birth-Weight Infants
- Age-Related Differences in Manifestation of Cushing Disease Identified